AdvisorShares Investments LLC Acquires Shares of 1,100 argenex SE $ARGX

AdvisorShares Investments LLC acquired a new stake in argenex SE (NASDAQ:ARGX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,100 shares of the company’s stock, valued at approximately $925,000.

Other hedge funds also recently bought and sold shares of the company. Abound Wealth Management grew its position in argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after acquiring an additional 32 shares during the last quarter. Sound Income Strategies LLC bought a new position in shares of argenex during the 4th quarter worth $28,000. Ameriflex Group Inc. bought a new position in shares of argenex during the 3rd quarter worth $32,000. Sunbelt Securities Inc. bought a new position in shares of argenex during the 3rd quarter worth $36,000. Finally, Aventura Private Wealth LLC bought a new position in shares of argenex during the 4th quarter worth $38,000. Institutional investors own 60.32% of the company’s stock.

argenex Price Performance

Shares of ARGX stock opened at $835.99 on Friday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The stock’s 50-day moving average is $779.30 and its 200 day moving average is $815.27. The company has a market cap of $51.99 billion, a P/E ratio of 37.22, a PEG ratio of 1.33 and a beta of 0.46.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The business had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, analysts anticipate that argenex SE will post 25.27 EPS for the current year.

Analyst Upgrades and Downgrades

ARGX has been the topic of a number of recent research reports. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Robert W. Baird increased their price target on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. Oppenheimer dropped their price target on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research report on Thursday, April 2nd. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Finally, Citizens Jmp increased their price target on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,017.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.